Napro Biotherapeutics (NASDAQ:NPRO)
Historical Stock Chart
From Jun 2019 to Jun 2024
![Click Here for more Napro Biotherapeutics Charts. Click Here for more Napro Biotherapeutics Charts.](/p.php?pid=staticchart&s=N%5ENPRO&p=8&t=15)
NaPro BioTherapeutics Announces the Appointment of Anne Bailey as Vice President
and General Manager, Genomics Division
BOULDER, Colo., Dec. 22 /PRNewswire-FirstCall/ -- NaPro BioTherapeutics, Inc
announced today the appointment of Anne Bailey as its Vice President of
Diagnostics and Reagents and General Manager of its Genomics Division. Ms.
Bailey has over 25 years of management experience in the medical diagnostics,
reference laboratory and research products industries. Ms. Bailey received her
B.S. in Biology/Chemistry from Samford University and an M.S. in Biochemistry
from Johns Hopkins University. Most recently Ms. Bailey served as Vice
President of Diagnostics at Variagenics and has held additional management
positions at Avitech Diagnostics, Photest Diagnostics and Metpath, Inc.
Ms. Bailey commented on her appointment, "I am excited to join NaPro's team of
talented scientists at this pivotal time in the company's development. I believe
there is a wealth of untapped commercial value for both therapeutic and
diagnostic applications for NaPro's gene editing technology. I look forward to
participating in the commercialization of this unique platform technology."
NaPro also announced that Mr. Jeffrey White, the President of NaPro's Genomics
Division, would be leaving the company, effective January 2, 2004, to pursue
other opportunities. Mr. White will continue as a consultant to the Company.
"We are delighted to have a manager of Anne Bailey's strong background and
experience joining us at this time in our Genomics Division," commented Leonard
P. Shaykin, Chairman and CEO of NaPro. "At the same time, we are sorry to see
Jeff White leave NaPro. He has established a strong foundation for our
therapeutic and diagnostic programs within the Genomics Division. We all wish
him well in his future endeavors."
About NaPro BioTherapeutics
NaPro BioTherapeutics, Inc., is a life science company focused on the
development of targeted therapies for the treatment of cancer and hereditary
disease.
Forward Looking Statements
The statements in this news release that are not historical facts are
forward-looking statements that represent management's beliefs and assumptions
as of the date of this news release, based on currently available information.
Forward-looking statements can be identified by the use of words such as
"believes," "intends," "estimates," "may," "will," "should," "anticipated,"
"expected" or comparable terminology or by discussions of strategy. Although
the Company believes that the expectations reflected in such forward-looking
statements are reasonable, it cannot assure that these expectations will prove
to be correct. Such statements involve risks and uncertainties including: risks
associated with development of the genomics, gene editing and targeted
businesses, including competition from companies in similar businesses,
limitations on the ability to market products because of the intellectual
property rights of third parties, the ability to obtain, maintain and enforce
patents; the costs of continuing development of any or all of the Company's
development programs; the timing of when those programs will enter the clinic;
the successful commercialization of the Company's platform technologies; the
fact that the Company's business will require substantial additional investment
that the Company has not secured; and the risk that the Company's cash not be
sufficient to fund the Company's strategic plans for the initial development new
proprietary therapeutic candidates; and all of those factors identified under
the captions "Risk Factors," "Special Note Regarding Forward Looking Statements"
or "Cautionary Note Regarding Forward Looking Statements" in the Company's
documents filed from time to time with the SEC, including the Company's
registration statement on Form S-3, as amended, dated August 8, 2003, its Annual
Report on Forms 10-K and 10-K/A for the year ending December 31, 2002 filed with
the SEC on March 27, April 30, August 8 and October 24, 2003, and its Quarterly
Report on Form 10-Q for the quarter ended July 2, 2003 filed with the Securities
and Exchange Commission on August 8, 2003. Should one or more of these risks
materialize (or the consequences of such a development worsen), or should the
underlying assumptions prove incorrect, actual results could differ materially
from those forecasted or expected. The Company disclaims any intention or
obligation to update publicly or revise such statements whether as a result of
new information, future events or otherwise.
DATASOURCE: NaPro BioTherapeutics, Inc.
CONTACT: L. Robert Cohen, Vice President, Investor Relations of NaPro
BioTherapeutics, +1-212-218-8715; or Investors, Lilian Stern of Stern Investor
Relations, +1-212-362-1200, for NaPro BioTherapeutics; or Media, Peter
Steinerman, +1-516-374-3031, for NaPro BioTherapeutics